4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Amylyx Pharmaceuticals was named by Zacks Investment Research as one of four biotech stocks with major second-half pipeline catalysts this year, including potential FDA decisions and late-stage data readouts in 2026.
Why it matters — An AMLX watcher would care because the article signals that upcoming FDA decisions and late-stage trial results in the second half could be significant catalysts for the company's stock performance.